EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer

Xiaoniu He iD, Yuanpei Li, Jian Li, Yu Li, Sijie Chen, Xia Yan, Zhangrong Xie, Jiangfeng Du, Guoan Chen, Jianbo Song, Qi Mei

Advanced Science · 2025-04 · 12 (14)

DOI: 10.1002/advs.202413121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 14.02.2025. Verfasst von Xiaoniu He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, Ch…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Methyltransferases, Histone Deacetylase 2. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation of Shanxi Bethune Hospital, Fundamental Research Program of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current treatment of triple‐negative breast cancer (TNBC) is still primarily based on platinum‐based chemotherapy. However, TNBC cells frequently develop resistance to platinum and experience relapse after drug withdrawal. It is crucial to specifically target and eliminate cisplatin‐tolerant cells after platinum administration. Here, it is reported that upregulated N 6 ‐methyladenosine (m 6 A) modification drives the development of resistance in TNBC cells during cisplatin treatment. Mechanistically, histone deacetylase 2 (HDAC2) mediates delactylation of methyltransferase‐like 3 (METTL3), facilitating METTL3 interaction with Wilms’‐tumor‐1‐associated protein and subsequently increasing m 6 A of transcript‐associated DNA damage repair. This ultimately promotes cell survival under cisplatin. Furthermore, pharmacological inhibition of HDAC2 using Tucidinostat can enhance the sensitivity of TNBC cells to cisplatin therapy. This study not only elucidates the biological function of lactylated METTL3 in tumor cells but also highlights its negative regulatory effect on cisplatin resistance. Additionally, it underscores the nonclassical functional mechanism of Tucidinostat as a HDAC inhibitor for improving the efficacy of cisplatin against TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDrug Resistance, NeoplasmMethyltransferasesHistone Deacetylase 2DNA RepairHumansFemaleCisplatinCell Line, TumorDNA DamageAntineoplastic Agents

Stichwörter der Autor:innen

HDAC2METTL3TNBCchemotherapy resistancelactylation

Substanzen

MethyltransferasesHistone Deacetylase 2METTL3 protein, humanCisplatinHDAC2 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Institute of Molecular Medicine and Experimental Immunology, University Clinic of Rheinische Friedrich-Wilhelms-University, 53127, Bonn, Germany.
  • Department of Human Cell Biology and Genetics, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, 518…
  • Department of Medical Imaging, Shanxi Key Laboratory of Intelligent Imaging and Nanomedicine, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

ORCID-Profile: Xiaoniu He

Förderung

  • Science Foundation of Shanxi Bethune Hospital
  • Fundamental Research Program of Shanxi Province

Zitieren

APA

He, X., Li, Y., Li, J., Li, Y., Chen, S., Yan, X., Xie, Z., Du, J., Chen, G., Song, J., & Mei, Q. (2025). HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer. Advanced Science, 12(14). https://doi.org/10.1002/advs.202413121

Vancouver

He X, Li Y, Li J, Li Y, Chen S, Yan X, et al. HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2025;12(14). doi:10.1002/advs.202413121

BibTeX
@article{He2025,
  author = {He, Xiaoniu and Li, Yuanpei and Li, Jian and Li, Yu and Chen, Sijie and Yan, Xia and Xie, Zhangrong and Du, Jiangfeng and Chen, Guoan and Song, Jianbo and Mei, Qi},
  title = {HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {14},
  doi = {10.1002/advs.202413121}
}
Kostenlos starten →